PMID- 32267188
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 19
IP  - 5
DP  - 2020 May
TI  - Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer.
PG  - 589-599
LID - 10.1080/14740338.2020.1753697 [doi]
AB  - Introduction: Lung cancer is the most prevalent malignant tumors worldwide. Over 
      the past decade, the emergence of epidermal growth factor receptor-tyrosine 
      kinase inhibitors (EGFR-TKIs) has ushered in a new era of lung cancer treatment. 
      Therefore, clinical trials investigating the efficacy and safety of these drugs 
      are important.Areas covered: This review provides an overview on the safety of 
      three classes of EGFR-TKIs and discusses the adverse events (AEs) and reactions 
      reported in the literature.Expert opinion: EGFR-TKIs significantly improve 
      progression-free survival and overall survival in non-small cell lung cancer 
      (NSCLC) patients with an activating mutation of EGFR. However, EGFR-TKIs also 
      block the EGFR-regulating pathways in the skin and gastrointestinal tract and 
      cause AEs, including diarrhea, liver toxicity, skin disease, stomatitis, 
      interstitial lung disease, and ocular toxicity, which have detrimental effects on 
      quality of life and drug compliance. Clinicians should understand how to prevent 
      and control these adverse reactions, which can often be achieved by dose 
      reduction, discontinuation of treatment, or switching to another drug.
FAU - Zhou, Jia-Ying
AU  - Zhou JY
AD  - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, School of Medicine, South China University 
      of Technology, Guangzhou, China.
FAU - Liu, Si-Yang
AU  - Liu SY
AD  - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, School of Medicine, South China University 
      of Technology, Guangzhou, China.
FAU - Wu, Yi-Long
AU  - Wu YL
AD  - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, School of Medicine, South China University 
      of Technology, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200428
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - ErbB Receptors/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - Mutation
MH  - Progression-Free Survival
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Quality of Life
MH  - Survival Rate
OTO - NOTNLM
OT  - Epidermal growth factor receptor-tyrosine kinase inhibitors
OT  - adverse event
OT  - management
OT  - non-small cell lung cancer
EDAT- 2020/04/09 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PHST- 2020/04/09 06:00 [entrez]
AID - 10.1080/14740338.2020.1753697 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2020 May;19(5):589-599. doi: 10.1080/14740338.2020.1753697. 
      Epub 2020 Apr 28.